ERBB2 and neoplasm: Majority of the patients presented with ≤2 cm tumors (64.3%), histologic grade 1 tumor (66%), no lymph node metastasis (70.1%), positive ER status (82.5%), negative HER2 status (74.8%), and Luminal A molecular subtype (47.8%) tumor.